Evidence map›Paper›PMID 27956445›Full record

ReviewClinical medicine (London, England)2016

Update in diagnosis and management of interstitial lung disease.

Theresia A Mikolasch, Helen S Garthwaite, Joanna C Porter

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical medicine (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Pulmonary [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Transbronchial cryobiopsy for diagnosing parenchymal lung diseases: real-life experience from a tertiary referral center.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2021
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Theresia A MikolaschUCL Respiratory, Univeristy College London and Interstitial Lung Disease Service, University College London NHS Foundation Trust, London, UK.
Helen S GarthwaiteUCL Respiratory, Univeristy College London and Interstitial Lung Disease Service, University College London NHS Foundation Trust, London, UK.
Joanna C PorterUCL Respiratory, University College London and Interstitial Lung Disease Service, University College London NHS Foundation Trust, London, UK Joanna.porter@ucl.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The field of interstitial lung disease (ILD) has undergone significant evolution in recent years, with an increasing incidence and more complex, ever expanding disease classification. In their most severe forms, these diseases lead to progressive loss of lung function, respiratory failure and eventually death. Despite notable advances, progress has been challenged by a poor understanding of pathological mechanisms and patient heterogeneity, including variable progression. The diagnostic pathway is thus being continually refined, with the introduction of tools such as transbronchial cryo lung biopsy and a move towards genetically aided, precision medicine. In this review, we focus on how to approach a patient with ILD and the diagnostic process.

Indexed as

Lung Diseases, InterstitialBiopsyHumansCryoscopic lung biopsyidiopathic pulmonary fibrosisinterstitial lung disease

Identifiers

PMID27956445
PMCPMC6329571

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.